Human Papillomavirus, Herpes Zoster, and Hepatitis B Vaccinations in Immunocompromised Patients: An Update for Pharmacists.

Michelle R PaulsenNikitha R PatelCarol SulisFrancis A FarrayeShubha Bhat

Published in: Journal of pharmacy practice (2020)

The 9vHPV can be used in men and women ages 9 to 45 years old regardless of immune status. RZV safety and efficacy in several immunocompromised populations has been demonstrated; however, manufacturers and major societies have yet to update their recommendations. HepB-CpG may be used in most immunocompromised patients yet remains under-utilized.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
gene expression
extracorporeal membrane oxygenation
mechanical ventilation